IP Library Granted Patent US 9,952,230
Granted Patent B2
US 9,952,230 · App. 14/116,155 · Granted Apr 24, 2018

Method of inhibiting nonspecific reaction in PIVKA-II assay reagent

Inventors: Takuji Matsumoto (Ibaraki-ken, JP); Mitsuaki Yamamoto (Chiba-ken, JP)
Assignee: SEKISUI MEDICAL CO., LTD.
G01N33/86G01N33/541G01N33/542G01N33/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,952,230
App. No.
14/116,155
Granted
Apr 24, 2018
Kind
B2
Abstract

A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.

Claims (26)

1. A method of measuring concentration of PIVKA-II in a biological sample comprising the steps of:

bringing first carrier particles to which a first monoclonal antibody is immobilized and second carrier particles to which a second monoclonal antibody is immobilized into contact with the biological sample in which prothrombin may exist under the presence of divalent metal ions; and

optically measuring agglutination of said first carrier particles and said second carrier particles to determine the concentration of PIVKA-II,

wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,

wherein both antibodies bind to different epitopes, and

wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ and are not derived from the biological sample.

2. The method according to claim 1 , wherein the divalent metal ions are ions of one or more selected from the group consisting of Mg 2+ and Ca 2+ .

3. The method according to claim 1 or 2 , wherein the first or second carrier particles are latex particles.

4. The method according to claim 1 , wherein the step of bringing into contact and the step of measuring are performed in the same reaction solution or in the same reaction vessel.

5. A reagent for measuring concentration of PIVKA-H through an agglutination reaction comprising:

first carrier particles to which a first monoclonal antibody is immobilized;

second carrier particles to which a second monoclonal antibody is immobilized; and

divalent metal ions,

wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,

wherein both antibodies bind to different epitopes, and

wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ .

6. The reagent according to claim 5 , wherein neither the first carrier particles nor the second carrier particles are fluorescent carrier particles.

7. A kit of parts for measuring concentration of PIVKA-II through an agglutination reaction comprising:

a first reagent containing divalent metal ions; and

a second reagent containing first carrier particles to which a first monoclonal antibody is immobilized and second carrier particles to which a second monoclonal antibody is immobilized,

wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,

wherein both antibodies bind to different epitopes, and

wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ .

8. The kit of parts according to claim 7 , wherein neither the first carrier particles nor the second carrier particles are fluorescent carrier particles.

9. The method according to claim 1 , wherein the biological sample is a sample in which prothrombin exists.

10. The method according to claim 1 , wherein the biological sample is blood, serum, plasma, or lymph fluid.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Oct 11, 2017
From: EIDIA CO., LTD.; SEKISUI MEDICAL CO., LTD.
To: SEKISUI MEDICAL CO., LTD.
Reel/Frame 044219/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2013
From: MATSUMOTO, TAKUJI; YAMAMOTO, MITSUAKI
To: SEKISUI MEDICAL CO., LTD.; EIDIA CO., LTD.
Reel/Frame 031762/0745 →
Priority Claims (1)
JP 2011-114776 · May 23, 2011 · national
Continuity (1)
Related Publication 20140113387A1 · Apr 24, 2014